Added to YB: 2025-11-10
Pitch date: 2025-11-04
MRUS [neutral]
Merus N.V.
+2.12%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Market Cap
$7.3B
Pitch Price
$94.92
Price Target
97.00 (+0%)
Dividend
N/A
EV/EBITDA
-17.68
P/E
-17.90
EV/Sales
114.35
Sector
Biotechnology
Category
special_situation
3 quick merger arb ideas at >10% yield - Merus N.V.
MRUS (merger arb): Genmab acquiring at $97/share, closes end Q4/early Q1. Current price $94.82 offers 2.2% absolute/11.1% annualized return - high for this transaction type. Spread likely wide due to arb capital stretched across multiple biotech deals (AKRO MTSR RNA ATXS AVDL). Low regulatory risk.
Read full article (1 min)